The purpose of the Biobanking and Correlative Sciences (BCS) Core is to enhance the peer reviewed, funded research activities of KCI members whose research requires IRB-approved access to patient tissue for preclinical and clinical studies and to support clinical trials by managing tissue specimens and providing circulating tumor cell counting. The BCS Core is grouped in the Cross Disciplinary Research Core Cluster which, in addition to the BCS Core, includes the Biostatistics, Genomics, and Pharmacology Cores. The BCS Core provides KCI investigators with high quality, well-annotated tumor tissue specimens for pre- clinical studies and coordinates requests for tumor tissues with the Genomics, Pharmacology and Proteomics Cores. Disease site-specific pathologists review tissues for selection of appropriate samples. This ensures there is appropriate and adequate tissue in the amounts and numbers needed for a given study to provide biologically meaningful results as determined by the Biostatistics Core. Institutional funds support the contributions of the pathologists. Fresh frozen specimens in the KCI Biobank are stored in eight -80?C freezers, which are temperature monitored and have back up emergency power. All specimens are barcoded and stored in cryosafe containers. Secured cabinets store formalin-fixed paraffin embedded (FFPE) specimens and any prepared slides from the biospecimens. Each biospecimen is logged into the KCI database, OnCore, with its precise location, associated informed consent, pathology report, and amount of available tissue. Histology services are supported by a tissue processor, a tissue embedder, microtomes, a cryostat, and other ancillary histology equipment. For pharmacodynamic assays, the core contains a Janssen Cell Search Circulating Tumor Cell system, which enables investigators to enumerate and/or isolate circulating tumor cells. The services provided by the Biobanking and Correlative Sciences Core have contributed to 21 peer- reviewed publications during the current review period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-38
Application #
9836635
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
38
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
McKnight, Brooke N; Viola-Villegas, Nerissa T (2018) Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging. Breast Cancer Res 20:130
McFall, Thomas; McKnight, Brooke; Rosati, Rayna et al. (2018) Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem 293:1163-1177
Dyson, Greg; Farran, Batoul; Bolton, Susan et al. (2018) The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. Am J Cancer Res 8:2088-2095
Greenwald, Mark K; Ruterbusch, Julie J; Beebe-Dimmer, Jennifer L et al. (2018) Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer :
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58

Showing the most recent 10 out of 826 publications